A. Preti et al., CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE LYMPHOCYTIC-LEUKEMIA AND MYELOPEROXIDASE-POSITIVE BLASTS BY ELECTRON-MICROSCOPY, Hematologic pathology, 8(4), 1994, pp. 155-167
The purpose of the study was to analyze the clinical and laboratory ch
aracteristics of patients with acute lymphocytic leukemia (ALL) who ex
hibited myeloperoxidase-positive blasts by electron microscopy (EM-MPO
-positive), and assess their response to therapy and their prognosis.
Since 1988, 21 adults with newly-diagnosed ALL and EM-MPO-positive bla
sts were referred to our service. In addition to documentation of thei
r clinical and hematopathologic characteristics, patients underwent cy
togenetic, immunophenotypic, molecular, and electron-microscopic evalu
ations. Twenty patients were treated with the vincristine-Adriamycin-d
examethasone (VAD) regimen, and one patient was induced with amsacrine
and high-dose cytosine arabinoside (ara-C). The 21 patients were amon
g 141 patients with ALL (15%) seen during the same period. Their media
n age was 46 years (Pange 15 to 77 years). The immunophenotype was T-c
ell ALL in 12 patients (57%). Karyotypic studies did not demonstrate s
pecific recurrent abnormalities. The median percentage of EM-MPO-posit
ive blasts was 15% (range 3% to 45%). Eighteen patients (85%) had high
-risk ALL. With induction chemotherapy 15 of 20 (75%) receiving VAD th
erapy achieved a complete remission (CR). However, the median CR durat
ion was 18 months, and the median survival was 18 months with a 3-year
disease-free survival rate of 25%. There were eight relapses and one
lineage switch to acute myelogenous leukemia (AML). Patients with ALL
and EM-MPO-positive disease are a unique subgroup with long-term poor
prognosis on conventional anti-ALL therapy, and may benefit from inten
sification treatments with agents effective against AML.